187 results
DEFA14A
LUMO
Lumos Pharma Inc
12 Apr 24
Additional proxy soliciting materials
5:27pm
Definitive Additional Materials
☐ Soliciting Material Pursuant to § 240.14a-12
LUMOS PHARMA, INC.
(Name of Registrant as Specified In Its Charter … :
5.Total fee paid:
☐ Fee paid previously with preliminary materials.
☐ Check box if any part of the fee is offset as provided by Exchange Act Rule
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 Nov 23
Other Events
4:38pm
(10%)
Supplementary Materials
44 Historical Data Show LUM-201 Augments Growth Hormone (GH) Pulsatility and Increases Circulating IGF-1 Adults
8-K
EX-99.2
x4nndp
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
EX-99.2
q8n1gvgisnv 71
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.2
srqr3
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
vabon
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
EX-99.2
91yq83
3 May 23
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
4:49pm
DEFA14A
9ef7m8 uwimgw1b3idtd
31 Mar 23
Additional proxy soliciting materials
4:43pm
8-K
EX-99.2
4x2pz9idwlqkglssz8
12 Dec 22
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
5:20pm
8-K
EX-99.2
yziz2p7c6wlg 8v853f
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
424B5
1h87602y uz6v
29 Aug 22
Prospectus supplement for primary offering
5:14pm